文献速递乳腺癌放疗姑息放疗与转移瘤

肿瘤治疗模式与放射治疗使用中价值导向变化的关联

Association of the Oncology Care Model With Value-Based Changes in Use of Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-02-09

该研究利用美国联邦医疗保险行政数据,采用双重差分分析评估肿瘤治疗模式(OCM)对乳腺癌术后放疗使用及骨转移姑息放疗分割模式的影响。在27,859例乳腺癌术后 episode 和19,366例转移性骨病 episode 中,OCM 对放疗使用和分割模式均无显著影响。作者认为未来直接针对放射肿瘤学提供者的支付模式可能更能改善放疗价值。

要点

  • OCM 对乳腺癌术后放疗总体使用无影响(DID=0.4%,90%CI -1.7%~2.4%)。
  • OCM 对骨转移姑息放疗分割模式无影响(≤10次 DID=-1.1%,90%CI -2.6%~0.4%)。
  • 无论机构是否有放射肿瘤科医生,结果相似。

核心结论

  • OCM 对乳腺癌保乳术后放疗使用或转移性骨病放疗分割模式均无影响。
  • 作者认为未来直接针对放射肿瘤学提供者的支付模式可能更能改善放疗价值。

研究设计与样本

  • 利用美国联邦医疗保险与医疗补助服务中心行政数据,识别在 OCM 及倾向性匹配对照机构开始化疗 episode 的传统按服务付费医疗保险受益人。
  • 采用双重差分分析评估 OCM 对乳腺癌术后放疗使用、乳腺癌调强放疗和超大分割使用、以及乳腺癌或前列腺癌骨转移放疗分割模式的影响。
  • 额外按机构有无放射肿瘤科医生进行分层分析。

主要发现

  • 在27,859例乳腺癌术后 episode 中,OCM 对术后放疗总体使用无影响(DID=0.4%,90%CI -1.7%~2.4%)。
  • 在该背景下,OCM 对调强放疗使用无影响(DID=-0.6,90%CI -3.1~2.0)。
  • 在19,366例转移性骨病 episode 中,OCM 对骨转移姑息放疗分割模式无影响(≤10次 DID=-1.1%,90%CI -2.6%~0.4%;单次分割 DID=-0.2%,90%CI -1.9%~1.6%)。
  • 有和无放射肿瘤科医生的机构结果相似。
  • 因基线趋势存在差异的证据,未评估 OCM 对保乳术后超大分割放疗的影响。

局限性

  • 因基线趋势存在差异的证据,未评估 OCM 对保乳术后超大分割放疗的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation utilization for breast cancer and metastatic bone disease varies in modality, fractionation, and cost, despite evidence demonstrating equal effectiveness and consensus recommendations such as Choosing Wisely that advocate for higher value care. We assessed whether the Oncology Care Model (OCM), an alternative payment model for practices providing chemotherapy to patients with cancer, affected the overall use and value of radiation therapy in terms of Choosing Wisely recommendations. METHODS AND MATERIALS: We used Centers for Medicare & Medicaid Services administrative data to identify beneficiaries enrolled in traditional fee-for-service Medicare who initiated chemotherapy episodes at OCM and propensity-matched comparison practices. Difference-in-difference (DID) analyses evaluated the effect of OCM on overall use of postoperative radiation for breast cancer, use of intensity modulated radiation therapy and hypofractionation for breast cancer, and fractionation patterns for treatment of metastatic bone disease from breast or prostate cancer. We performed additional analyses stratified by the presence or absence of a radiation oncologist in the practice. RESULTS: Among 27,859 postoperative breast cancer episodes, OCM had no effect on overall use of radiation therapy after breast surgery (DID percentage point difference = 0.4%; 90% confidence interval [CI], -1.7%, 2.4%) or on use of intensity modulated radiation therapy in this setting (DID = -0.6; 90% CI, -3.1, 2.0). Among 19,366 metastatic bone disease episodes, OCM had no effect on fractionation patterns for palliation of bone metastases (DID for ≤10 fractions = -1.1%; 90% CI, -2.6%, 0.4% and DID for single fraction = -0.2%; 90% CI, -1.9%, 1.6%). Results were similar for practices with and without a radiation oncologist. We did not evaluate the effect of OCM on hypofractionated radiation after breast-conserving surgery owing to evidence of differential baseline trends. CONCLUSIONS: OCM had no effect on use of radiation therapy after breast-conserving surgery for breast cancer or on fractionation patterns for metastatic bone disease. Future payment models directly focused on radiation oncology providers may be better poised to improve the value of radiation oncology care.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kapadia NS, Brooks GA, Landrum MB, et al. Association of the Oncology Care Model With Value-Based Changes in Use of Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022. PMID: 35150787. doi:10.1016/j.ijrobp.2022.01.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。